EP0791012A1 - Peptides exhibiting oxytocin antagonistic activity - Google Patents

Peptides exhibiting oxytocin antagonistic activity

Info

Publication number
EP0791012A1
EP0791012A1 EP94921875A EP94921875A EP0791012A1 EP 0791012 A1 EP0791012 A1 EP 0791012A1 EP 94921875 A EP94921875 A EP 94921875A EP 94921875 A EP94921875 A EP 94921875A EP 0791012 A1 EP0791012 A1 EP 0791012A1
Authority
EP
European Patent Office
Prior art keywords
peptide
pharmaceutical composition
composition according
asn
nαmeorn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94921875A
Other languages
German (de)
French (fr)
Inventor
Carl-Johan Aurell
Per Melin
Anders Nilsson
Jerzy Trojnar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of EP0791012A1 publication Critical patent/EP0791012A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to new peptides exhibiting oxytocin antagonistic activity.
  • the peptides are built up of 7 amino acid residues and comprises an intramolecular ring structure. They can be used as active ingredients in pharmaceutical compositions for the inhibition of excessive uterus muscle contractions. These constitute the background for painful menstruations and premature labour.
  • vasotocin analogues do not have any side effects, but they have a limited biological half-life and thus give a rather short effect duration.
  • the enzymatic stability of the molecule, and thus the duration of the effect, is of major clinical importance at a single administration. Since the effect duration of these vasotocin analogues is comparatively short and the therapeutic dose is rather high, they have hitherto been administered intravenously in hospitals only.
  • the present invention comprises a new peptide of the formula:
  • Mpa is 3-mercaptopropionic acid residue (-S-CH 2 -CH 2 -CO-)
  • X is D-tryptophan (D-Trp) or ⁇ - (2-Naphtyl) -D-alanine (D-Nal) lie is isoleucine
  • Y is alloisoleucine (allolle) or
  • CH 2 I and N ⁇ MeOrn is N ⁇ -methyl-ornithine.
  • One aspect of the invention is directed to a peptide according to the invention for use as an active ingredient in a medicament.
  • compositions which comprise at least one of the peptides according to the invention as active ingredient (s) in combination with pharmaceutically acceptable additives and/or diluents, and optionally enhancers.
  • pharmaceutically acceptable diluent preferably isotonic saline solution may be used.
  • additives such can be found in the literature, e.g. the US Pharmacopoeia, and these additives shall be chosen in conformity with the specific form of the composition for a specific administration route.
  • Enhancers which may be used are any enhancers known to facilitate absorption of a drug through a mucous membrane. Examples of absorption enhancers in nasal drug delivery has been disclosed by Merkus, F.W.H.
  • a composition according to the invention can be in a form which is suitable for intravenous, intranasal or oral administration.
  • a form which is suitable for oral administration may be a tablet which is taken orally and which preferably is coated with a layer which is dissolved mainly in the intestines so that the active ingredient can be absorbed through the intestinal mucous membrane.
  • An embodiment of this aspect of the invention is directed to a pharmaceutical composition according to the invention for use in therapeutic treatment of excessive uterus muscle contractions.
  • Yet another aspect of the invention is directed to a method of counteracting excessive uterus muscle contractions, whereby a pharmaceutical composition according to the invention is administered in a therapeutically effectiv amount to a woman who is in need of such a treatment.
  • the peptides according to the present invention have a specific effect on the uterus muscle and totally lack agonistic effect as well as antidiuretic effect and blood-pressure effect, resulting in high specificity, which means that possible clinical side effects are minimized.
  • the peptides according to the invention can be prepared in analogy with processes well known in the peptide field.
  • the compounds according to the invention may be prepared in conventional manner by incremental coupling of amino acids to one another in liquid phase, e.g. as described by Law, H.B. & Du Vigneaud, V. in Journal of the American Chemical Society 32, (1960) 4579-4581, Zhuze, A.L. , Jost, K. , Kasafirek, E. S_ Rudinger, J. in Collection of Czechoslovak Chemical Communications 22., (1964), 2648-2662, and modified by Larsson, L.-E., B Lindeberg, G., Melin, P. / Pliska, V. in the Journal of Medicinal Chemistry 21, (1978), 352-356.
  • the coupling of the amino acids to one another, whereby so-called peptide bonds are formed may also be carried out by use of a solid phase (usually a resin) as starting material, to which the C-terminal of the first amino acid is coupled, whereupon the C-terminal of the next amino acid is coupled to the N-terminal of the first amino acid etc.
  • the ring closure is performed as the last step of synthesis after or before the release of the complete peptide from the solid phase.
  • this so-called solid phase technique has been utilized in accordance with the disclosure according to Merrifield, R.B., J. Am. Chem. Soc. (1963), 35., 2149, Merrifield, R.B. Biochemistry (1964), 2, 1385 and K ⁇ nig, W. , Geiger, R., Chem. Ber. (1970), 103. 788.
  • peptides disclosed in the following examples were synthesized using the solid phase technique (J. M. Stewart, J.D. Young. Solid Phase Peptide Synthesis, Pierce Chemical Company) .
  • the peptides were purified by liquid chromatography (reversed phase) .
  • the stationary phase was composed of Kromasil®, 13 ⁇ or 5 ⁇ , 100 A, C 18 or C 8 (EKA Nobel, Sweden) and the mobile phase was acetonitrile/water having 0.1 % trifluoroacetic acid. Those fractions containing pure product (HPLC analysis) were pooled, evaporated and the product was freeze-dried from water.
  • the purity and structure of the peptides were determined by HPLC, amino acid analysis and FAB-MS.
  • Fmoc-homoCys(CH 2 CH 2 COOt-Bu) -OH was synthesized according to a publication of E. Prochazka et al, Collect. Czech. Chem. Commun. 1992, 52, 1335.
  • Fmoc-N ⁇ MeOrn(Pht) -OH was synthesized in the same way as the corresponding lysine derivative according to a publication of R. M. Freidinger et al, J. Org. Chem. 1983, 4£, 77.
  • TBTU 2- (1-H-benzotriazol-l-yl) -1,1,3,3-tetramethyl-uronium- tetrafluoroborate
  • MBHA 4-methyl-benzhydrylamine
  • Boc t-buthyloxycarbonyl
  • NMP N-methylpyrrolidone
  • HOBt 1-hydroxybenzotriazole
  • DBU l , 8 -diazabicyclo [5 .4 . 0] undec-7-ene
  • DMF Dimethylformamide
  • DIPEA Diisopropylethylamine
  • the peptide was synthesized according to a mixed Boc/Fmoc methodology on solid phase. Activation of the amino acids was made with TBTU/HOBt. The resin was of MBHA-type with the loading of 0.65 mmole/g, and 0.33 g was used for each synthesis. The first amino acid was N ⁇ Boc protected. The Boc group was removed with 50 % trifluoroacetic acid in dichloromethane. The rest of the synthesis followed the Fmoc strategy, i.e. N ⁇ -Fmoc protected amino acids were coupled to the free amino group of the previously coupled amino acid. The N ⁇ -Fmoc group was removed with 20 % piperidine in NMP.
  • the resin was treated with 20 % piperidine in NMP, followed by 50 % TFA in dichloromethane.
  • the peptide chain was thereafter cyclized while it was still attached to the resin, from D-Trp 2 to homoCys(CH 2 CH 2 COOH) 6 by activating with TBTU/HOBt, i.e. between positions 1 and 2.
  • the peptide was cleaved from the resin with liquid hydrogen fluoride-thiocresol- cresol-dimethylsulfide in the ratio of 8-0.25-0.75-1 at 0°C.
  • the resin was suspended in diethyl eter, filtrated and washed with additional diethyl eter.
  • the precipitated peptide was recovered from the resin by dissolving in acetic acid.
  • the acetic acid was evaporated and the residue freez-dried from water.
  • the freez- dried product was dissolved in ethanol, whereupon hydrazine hydrate was added in a molar excess.
  • the solution was stirred over night at room temperature, whereupon it was acidified with H 3 0 + and evaporated, and freez-dried from water.
  • the peptide was synthesized according to Fmoc methodology on solid phase. Activation of the amino acids was made with DIC/HOBt.
  • the resin was of TentaGel-S-type with RAM-linker (Rapp Polymere S 30023) .
  • the N ⁇ -Fmoc-groups were removed by 2% DBU in DMF.
  • the peptide was cleaved from the resin and deprotected with TFA/ethanedithiol/anisole in the ratio of 95:2.5:2.5.
  • the reaction mixture was filtered and the filtrate was concentrated.
  • the peptide was precipitated with diethyl ether.
  • the peptide was cyclized between the positions 1 and 2 by activation with TBTU/HOBt/DIPEA in DMF.
  • N ⁇ MeOrn(Pht) was deprotected by the addition of hydrazine hydrate. Following stirring overnight at room temperature, the solution was neutralized and evaporated.
  • the product was purified as disclosed above.
  • the peptide was synthesized according to the same methodology as in Example 2. At the purification performed as above the analogues with the R and S isomers of Ala( ⁇ -Et 2 ), respectively, were separated. The S isomer (Peptide 5) was eluated after the R isomer.
  • the enantiomeric forms of the respective peptide analogue was determined by first hydrolyzing and then derivatizing the amino acids, and analyzing the mixture on a chiral column by a gas chro athographic method.
  • Sprague Dawley rats 250 g in natural estrous were anaesthesized with Inactin (0.5 mg/lOO g body weight i.p.) .
  • the activity of the myometrium was measured with the aid of a catheter which had been fixed in the uterus cavity and which had been filled with modified Locke's solution.
  • the catheter was connected to a Statham P23d force transducer and the contractions were registered on a Grass polygraph (model 7D) .
  • the dose-effect curve for oxytocin (2.10 "4 - 5.10 "3 ⁇ mole/kg) was carried out.
  • Such an oxytocin dose (2 x) is selected which gives an effect corresponding to an intraluminar contraction pressure of 10-30 mg Hg and which lies on the linear part of the dose-effect curve.
  • the effects are measured as the net values of the integrated curve measured during 15 minutes after the injection.
  • the effect (eff x) of the agonist is calculated for its half dose (x) .
  • at least two doses of antagonist (Peptide 1-4) are injected in combination with the agonist dose (2 x) .
  • the antagonist dose corresponding to the effect (eff x) of the agonist dose (x) i.e. the I.D. dose, is obtained.
  • Table I The results are shown in Table I.
  • Antagonist tests effect duration.
  • a dose of the agonist is selected (5.10 "4 - 5.10 "3 ⁇ mole/kg) which gives an effect (the effect is measured during a 15 minutes period after agonist and antagonist administration, respectively, the contraction curve being integrated) corresponding to approximately 50 % of the maximum effect (ED 50 ) .
  • I ⁇ BLEJ Pharmacological data for oxytocin antagonists
  • Test substance ID nmol/kg Duration, min 0.75
  • Peptide 5 (inv.) 2.7 ⁇ 0.1 226 ⁇ 41
  • WO 92/00996 has the longest duration, having the formula
  • Peptide 3 (inv.) The peptide according to the invention having the formula
  • Peptide 4 (inv.) The peptide according to the invention having the formula

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A peptide having formula (I) wherein Mpa is 3-mercaptopropionic acid residue (-S-CH2-CH2-CO-); X is D-tryptophan (D-Trp) or β-(2-Naphtyl)-D-alanine (D-Nal); Ile is isoleucine; Y is alloisoleucine (alloIle) or (S)-2-Amino-3-ethyl-pentanoic acid (Ala(β-Et2)); Asn is asparagine; α-Abu is α-aminobutyric acid residue (II) and NαMeOrn is Nα-methyl-ornithine, is disclosed. The peptides may be used as an active ingredient in a medicament, especially in a pharmaceutical composition for therapeutic treatment of excessive uterus muscle contractions.

Description

PEPTIDES EXHIBITING OXYTOCIN ANTAGONISTIC ACTIVITY
The present invention relates to new peptides exhibiting oxytocin antagonistic activity. The peptides are built up of 7 amino acid residues and comprises an intramolecular ring structure. They can be used as active ingredients in pharmaceutical compositions for the inhibition of excessive uterus muscle contractions. These constitute the background for painful menstruations and premature labour.
Background
It has been previously shown (EP-A-0 112 809) that modifications of the vasotocin molecule in positions 1, 2, 4 and 8 give analogues, which strongly inhibit uterine contractions both in animal and human tests (Melin et al, J. Endocrinol. Ill, 125, 1986). These analogues have been shown to antagonize oxytocin or vasopressin induced contractions, and in clinical trials one analogue has been shown to counteract excessive uterus contractions in connections with painful menstruations and premature labour. (Akerlund, Acta Obst. Gynecol. Scand, 66, 459, 1987, Akerlund et al, Br. J. Obst. Gynecol, 94, 1040, 1987) . The above mentioned vasotocin analogues do not have any side effects, but they have a limited biological half-life and thus give a rather short effect duration. The enzymatic stability of the molecule, and thus the duration of the effect, is of major clinical importance at a single administration. Since the effect duration of these vasotocin analogues is comparatively short and the therapeutic dose is rather high, they have hitherto been administered intravenously in hospitals only.
In order to be able to utilize oxytocin antagonists in non- institutional care, it is necessary that the properties of the molecules with regard to the effect duration and bioavailability make them suitable for non-parenteral administration such as oral and/or intranasal administration. This puts special demands on the enzymatic stability of the molecules and the ability of the molecules to penetrate biological membranes, such as nasal and gut mucous membranes.
Appart from physical chemical properties one factor of importance for the penetrating ability is the size of the molecule. Thus, it is well-known that absorption through the gut mucousa increases with reduced molecular size. In WO 92/00996 is shown that derivatives of pituitary posterior lobe hormones built up of 8 amino acids has a better bioavailability after oral ingestion than the corresponding derivative having 9 amino acids. However, the single derivative therein which is built up of 7 amino acids gave potency and effect duration results that were comparable to the reference substance having 9 amino acids, but approximately three times poorer results than the corresponding derivative having 8 amino acids. The peptides according to the present invention are built up of only 7 amino acids residues. Unexpectedly they exhibit comparatively high antagonistic activity and substantially longer effect duration than any of the molecules tested in WO 92/00996.
Thus, the chances are good for a high absorption to the blood after intranasal or oral administration, which has been verified for two compounds (Peptide 3 and 4) in intranasal and oral animal models.
Description of the invention
The present invention comprises a new peptide of the formula:
Mpa-X-Ile-Y-Asn-α-Abu-NαMeOrn-NH2
1 I wherein
Mpa is 3-mercaptopropionic acid residue (-S-CH2-CH2-CO-) X is D-tryptophan (D-Trp) or β- (2-Naphtyl) -D-alanine (D-Nal) lie is isoleucine
Y is alloisoleucine (allolle) or
(S) -2-Amino-3-ethyl-pentanoic acid (Ala(β-Et2)) Asn is asparagine α-Abu is α-aminobutyric acid residue (-NH-CH-CO-)
I
CH2 I
CH2 I and NαMeOrn is Nα-methyl-ornithine. One aspect of the invention is directed to a peptide according to the invention for use as an active ingredient in a medicament.
Another aspect of the invention is directed to pharmaceutical compositions, which comprise at least one of the peptides according to the invention as active ingredient (s) in combination with pharmaceutically acceptable additives and/or diluents, and optionally enhancers. As pharmaceutically acceptable diluent preferably isotonic saline solution may be used. As to the other pharmaceutically acceptable additives, such can be found in the literature, e.g. the US Pharmacopoeia, and these additives shall be chosen in conformity with the specific form of the composition for a specific administration route. Enhancers which may be used are any enhancers known to facilitate absorption of a drug through a mucous membrane. Examples of absorption enhancers in nasal drug delivery has been disclosed by Merkus, F.W.H. . et al in the Journal of Controlled Release, 24 (1993) 201-208. Among the absorption enhancers mentioned are surfactants, bile acids, fusidates, fosfolipides and cyclodextrins. A composition according to the invention can be in a form which is suitable for intravenous, intranasal or oral administration. A form which is suitable for oral administration may be a tablet which is taken orally and which preferably is coated with a layer which is dissolved mainly in the intestines so that the active ingredient can be absorbed through the intestinal mucous membrane.
An embodiment of this aspect of the invention is directed to a pharmaceutical composition according to the invention for use in therapeutic treatment of excessive uterus muscle contractions. Yet another aspect of the invention is directed to a method of counteracting excessive uterus muscle contractions, whereby a pharmaceutical composition according to the invention is administered in a therapeutically effectiv amount to a woman who is in need of such a treatment.
The peptides according to the present invention have a specific effect on the uterus muscle and totally lack agonistic effect as well as antidiuretic effect and blood-pressure effect, resulting in high specificity, which means that possible clinical side effects are minimized.
Preparation of the peptides according to the invention
The peptides according to the invention can be prepared in analogy with processes well known in the peptide field.
For example, the compounds according to the invention may be prepared in conventional manner by incremental coupling of amino acids to one another in liquid phase, e.g. as described by Law, H.B. & Du Vigneaud, V. in Journal of the American Chemical Society 32, (1960) 4579-4581, Zhuze, A.L. , Jost, K. , Kasafirek, E. S_ Rudinger, J. in Collection of Czechoslovak Chemical Communications 22., (1964), 2648-2662, and modified by Larsson, L.-E., B Lindeberg, G., Melin, P. / Pliska, V. in the Journal of Medicinal Chemistry 21, (1978), 352-356. The coupling of the amino acids to one another, whereby so-called peptide bonds are formed, may also be carried out by use of a solid phase (usually a resin) as starting material, to which the C-terminal of the first amino acid is coupled, whereupon the C-terminal of the next amino acid is coupled to the N-terminal of the first amino acid etc. The ring closure is performed as the last step of synthesis after or before the release of the complete peptide from the solid phase. In the following examples this so-called solid phase technique has been utilized in accordance with the disclosure according to Merrifield, R.B., J. Am. Chem. Soc. (1963), 35., 2149, Merrifield, R.B. Biochemistry (1964), 2, 1385 and Kδnig, W. , Geiger, R., Chem. Ber. (1970), 103. 788.
General description of synthesis
The peptides disclosed in the following examples were synthesized using the solid phase technique (J. M. Stewart, J.D. Young. Solid Phase Peptide Synthesis, Pierce Chemical Company) .
The peptides were purified by liquid chromatography (reversed phase) . The stationary phase was composed of Kromasil®, 13 μ or 5 μ, 100 A, C18 or C8 (EKA Nobel, Sweden) and the mobile phase was acetonitrile/water having 0.1 % trifluoroacetic acid. Those fractions containing pure product (HPLC analysis) were pooled, evaporated and the product was freeze-dried from water.
The purity and structure of the peptides were determined by HPLC, amino acid analysis and FAB-MS.
The trifuntional amino acids were protected as follows:
Fmoc-D-Trp(Boc) -OH Fmoc-Asn(Trt) -OH Fmoc-homoCys(CH2CH2C00t-Bu) -OH F oc-NαMeOrn(Pht) -OH The two last mentioned derivatives are not commercially available.
Fmoc-homoCys(CH2CH2COOt-Bu) -OH was synthesized according to a publication of E. Prochazka et al, Collect. Czech. Chem. Commun. 1992, 52, 1335.
Fmoc-NαMeOrn(Pht) -OH was synthesized in the same way as the corresponding lysine derivative according to a publication of R. M. Freidinger et al, J. Org. Chem. 1983, 4£, 77.
(R,S) -2-amino-3-ethyl pentanoic acid was synthesized according to a publication of K. Ersler et al, Collect. Czech. Chem. Commun. __X, 1966, 4563.
The Fmoc derivatives of (R,S) -2-amino-3-ethyl pentanoic acid and alloisoleucine were synthesized according to a publication of P. B. W. Ten Kortenaar, et al, Int. J. Peptide Protein Res., 1986, 21, 398.
The following abbreviations have been used:
TBTU = 2- (1-H-benzotriazol-l-yl) -1,1,3,3-tetramethyl-uronium- tetrafluoroborate MBHA = 4-methyl-benzhydrylamine
Boc = t-buthyloxycarbonyl
Fmoc = 9-fluorenylmethoxycarbonyl
NMP = N-methylpyrrolidone
TFA = Trifluoroacetic acid DIC = Diisopropyl carbodiimide
HOBt = 1-hydroxybenzotriazole
DBU = l , 8 -diazabicyclo [5 .4 . 0] undec-7-ene DMF = Dimethylformamide DIPEA = Diisopropylethylamine Pht = Phthaloyl Trt = Triphenylmethyl (Trityl)
E am le 1 Peptide 3
( -NαMeOrnNH2) CH2 -CH2-CH2-NH2 CH2CH2CO-D-Trp- Ile-alloIle-Asn-NH-CH-CO-N-CH-CO-NH2
CH — CH2 CH3
The peptide was synthesized according to a mixed Boc/Fmoc methodology on solid phase. Activation of the amino acids was made with TBTU/HOBt. The resin was of MBHA-type with the loading of 0.65 mmole/g, and 0.33 g was used for each synthesis. The first amino acid was NαBoc protected. The Boc group was removed with 50 % trifluoroacetic acid in dichloromethane. The rest of the synthesis followed the Fmoc strategy, i.e. Nα-Fmoc protected amino acids were coupled to the free amino group of the previously coupled amino acid. The Nα-Fmoc group was removed with 20 % piperidine in NMP. When all the amino acids had been coupled to the resin, the resin was treated with 20 % piperidine in NMP, followed by 50 % TFA in dichloromethane. The peptide chain was thereafter cyclized while it was still attached to the resin, from D-Trp2 to homoCys(CH2CH2COOH)6 by activating with TBTU/HOBt, i.e. between positions 1 and 2. The peptide was cleaved from the resin with liquid hydrogen fluoride-thiocresol- cresol-dimethylsulfide in the ratio of 8-0.25-0.75-1 at 0°C. After evaporation of the hydrogen fluoride, the resin was suspended in diethyl eter, filtrated and washed with additional diethyl eter. The precipitated peptide was recovered from the resin by dissolving in acetic acid. The acetic acid was evaporated and the residue freez-dried from water. The freez- dried product was dissolved in ethanol, whereupon hydrazine hydrate was added in a molar excess. The solution was stirred over night at room temperature, whereupon it was acidified with H30+ and evaporated, and freez-dried from water. The product was purified in the same way as above. Yield: 4 mg. Purity (HPLC) = 95 %.
Example 2 Peptide 4
CH CH CO-D-Nal-Ile-alloIle-Asn-NHCHCO-NαMeOrn-NH,
■CH2—CH
The peptide was synthesized according to Fmoc methodology on solid phase. Activation of the amino acids was made with DIC/HOBt. The resin was of TentaGel-S-type with RAM-linker (Rapp Polymere S 30023) . The Nα-Fmoc-groups were removed by 2% DBU in DMF.
The peptide was cleaved from the resin and deprotected with TFA/ethanedithiol/anisole in the ratio of 95:2.5:2.5. The reaction mixture was filtered and the filtrate was concentrated. The peptide was precipitated with diethyl ether. Then the peptide was cyclized between the positions 1 and 2 by activation with TBTU/HOBt/DIPEA in DMF. After the cyclization NαMeOrn(Pht) was deprotected by the addition of hydrazine hydrate. Following stirring overnight at room temperature, the solution was neutralized and evaporated. The product was purified as disclosed above.
Yield: 11 mg
Purity (HPLC) : 99%
Example 3 Peptide 5
CH2CH2CO-D-Nal-Ile-Ala(β-Et2) -Asn-NHCHCO-NαMeOrn-NH2 1 2 3 4 5 6 7
S————————————————————CH —CH
The peptide was synthesized according to the same methodology as in Example 2. At the purification performed as above the analogues with the R and S isomers of Ala(β-Et2), respectively, were separated. The S isomer (Peptide 5) was eluated after the R isomer.
The enantiomeric forms of the respective peptide analogue was determined by first hydrolyzing and then derivatizing the amino acids, and analyzing the mixture on a chiral column by a gas chro athographic method.
Yield: 10 mg
Purity (HPLC) : 98%
PHARMACOLOGICAL TESTS In vivo tests, rat
Sprague Dawley rats (250 g) in natural estrous were anaesthesized with Inactin (0.5 mg/lOO g body weight i.p.) . The activity of the myometrium was measured with the aid of a catheter which had been fixed in the uterus cavity and which had been filled with modified Locke's solution. The catheter was connected to a Statham P23d force transducer and the contractions were registered on a Grass polygraph (model 7D) .
Antagonist tests. Inhibitory Dose (I.P.) [I.D. = that antagonist dose which inhibits an agonist dose (2 x) to an effect corresponding to the effect of half the agonist dose (x) ] .
At first, the dose-effect curve for oxytocin (2.10"4 - 5.10"3 μmole/kg) was carried out. Such an oxytocin dose (2 x) is selected which gives an effect corresponding to an intraluminar contraction pressure of 10-30 mg Hg and which lies on the linear part of the dose-effect curve. The effects are measured as the net values of the integrated curve measured during 15 minutes after the injection.
Then, the effect (eff x) of the agonist is calculated for its half dose (x) . Thereafter at least two doses of antagonist (Peptide 1-4) are injected in combination with the agonist dose (2 x) . By interpolating the dose-effect curve for the inhibition, the antagonist dose corresponding to the effect (eff x) of the agonist dose (x) , i.e. the I.D. dose, is obtained. The results are shown in Table I.
Antagonist tests, effect duration. (Dura ion, mϊn Q.75) Such a dose of the agonist is selected (5.10"4 - 5.10"3 μmole/kg) which gives an effect (the effect is measured during a 15 minutes period after agonist and antagonist administration, respectively, the contraction curve being integrated) corresponding to approximately 50 % of the maximum effect (ED50) .
Then a dose of the antagonist (Peptide 1-3) 0.8 - 4.10"8 mole/kg, which in combination with the agonist dose gives at least 50 % inhibition of the effect of the agonist dose only, is administered. Then, only the agonist dose is injected at 20 minutes intervals, the inhibition effect successively declining.
By interpolating, the period of time from administration of the inhibitor to when 75 % of the inhibition of the agonist effect has ceased, is obtained. The results are shown in Table I.
IΔBLEJ: Pharmacological data for oxytocin antagonists
In vivo, rat
Test substance ID nmol/kg Duration, min 0.75
Peptide 1 (ref.) 6.3 ± 0.8 29 ± 5
Peptide 2 (ref.) 2.2 ± 0.3 140 ± 19
Peptide 3 (inv.) 2.9 ± 0.2 248 ± 29 (preliminary 3.6 ± 0.6)
Peptide 4 (inv.) 1.8 ± 0.04 257 ± 20
Peptide 5 (inv.) 2.7 ± 0.1 226 ± 41 Peptide 1 (ref.) = Peptide according to EP 0 112 809 having the formula
Mpa-D-Tyr(Et) -Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2
1 I
Peptide 2 (ref.) = The tested peptide which according to
WO 92/00996 has the longest duration, having the formula
Mpa-D-Phe(p-Et) -Ile-Thr-Asn-α-Abu-Pro-Orn-NH2
Peptide 3 (inv.) = The peptide according to the invention having the formula
Mpa-D-Trp-Ile-alloIle-Asn-α-Abu-NαMeOrn-NH2
J I
Peptide 4 (inv.) = The peptide according to the invention having the formula
Mpa-D-Nal-Ile-alloIle-Asn-α-Abu-NαMeOrn-NH2
Peptide 5 (inv.) = The peptide according to the invention having the formula
Mpa-D-Nal-Ile-Ala(β-Et2) -Asn-α-Abu-NαMeOrn-NH2 J 1 It is evident from Table I that the Peptides 3, 4 and 5 according to the invention have a substantially prolonged effect duration with retained or improved (lower ID values) potency compared to the reference substances Peptide 1 and Peptide 2, respectively.

Claims

1. Peptide having the formula
Mpa-X-Ile-Y-Asn-α-Abu-NαMeOrn-NH2 i I wherein
Mpa is 3-mercaptopropionic acid residue (-S-CH2-CH2-CO-) X is D-tryptophan (D-Trp) or β- (2-Naphtyl) -D-alanine (D-Nal) lie is isoleucine Y is alloisoleucine (allolle) or
(S) -2-Amino-3-ethyl-pentanoic acid (Ala(β-Et2)) Asn is asparagine α-Abu is α-aminobutyric acid residue (-NH-CH-CO-)
NαMeOrn is Nα-methyl-ornithine.
2. Peptide according to claim 1 for use as an active ingredient in a medicament.
3. Pharmaceutical composition, c h a r a c t e r i z e d in that it comprises at least one peptide according to claim 1 as active ingredient(s) , together with pharmaceutically acceptable additives and/or diluents, and optionally enhancers.
4. Pharmaceutical composition according to claim 3, which is in a suitable administration form for intranasal administration.
5. Pharmaceutical composition according to claim 3, which is in a suitable administration form for intravenous administration.
6. Pharmaceutical composition according to claim 3, which is in a suitable administration form for oral administration.
7. Pharmaceutical composition according to any one of claims 3-6 for use in therapeutic treatment of excessive uterus muscle contractions.
8. A method of counteracting excessive uterus muscle contractions, in which a pharmaceutical composition according to any one of claims 3-6 is administered in a therapeutically effective amount to a woman in need of such treatment.
EP94921875A 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity Withdrawn EP0791012A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9302414 1993-07-13
SE9302414A SE501678C2 (en) 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide
PCT/SE1994/000674 WO1995002609A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity

Publications (1)

Publication Number Publication Date
EP0791012A1 true EP0791012A1 (en) 1997-08-27

Family

ID=20390606

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94921875A Withdrawn EP0791012A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity

Country Status (16)

Country Link
EP (1) EP0791012A1 (en)
JP (1) JPH09502427A (en)
KR (1) KR960702848A (en)
CN (1) CN1126999A (en)
AU (1) AU676071B2 (en)
CA (1) CA2163114A1 (en)
CZ (1) CZ9896A3 (en)
FI (1) FI960119A0 (en)
HU (1) HUT74874A (en)
IL (1) IL110267A0 (en)
NO (1) NO955059L (en)
PL (1) PL312568A1 (en)
SE (1) SE501678C2 (en)
TW (1) TW268009B (en)
WO (1) WO1995002609A1 (en)
ZA (1) ZA945090B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (en) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
CN108290929A (en) 2015-10-06 2018-07-17 辉凌公司 Manufacture the novel method of barusiban and its intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
SE9002384D0 (en) * 1990-07-09 1990-07-09 Ferring Ab DERIVATIVE OF BACKGROUND HORMONES
SE501677C2 (en) * 1993-06-18 1995-04-10 Ferring Bv Biologically active vasopressin analogs, pharmaceutical preparations containing them and their use in the manufacture of drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9502609A1 *

Also Published As

Publication number Publication date
HUT74874A (en) 1997-02-28
AU7240694A (en) 1995-02-13
KR960702848A (en) 1996-05-23
NO955059D0 (en) 1995-12-13
TW268009B (en) 1996-01-11
SE9302414D0 (en) 1993-07-13
FI960119A (en) 1996-01-10
CN1126999A (en) 1996-07-17
IL110267A0 (en) 1994-10-21
SE9302414L (en) 1995-01-14
FI960119A0 (en) 1996-01-10
CZ9896A3 (en) 1996-06-12
JPH09502427A (en) 1997-03-11
WO1995002609A1 (en) 1995-01-26
CA2163114A1 (en) 1995-01-26
NO955059L (en) 1995-12-13
AU676071B2 (en) 1997-02-27
ZA945090B (en) 1995-02-22
PL312568A1 (en) 1996-04-29
SE501678C2 (en) 1995-04-10
HU9503768D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
US6143722A (en) Heptapeptide oxytocin analogues
FI92326C (en) LHRH nonapeptide and decapeptide analogs useful as LHRH antagonists
HU224345B1 (en) Peptides with growth hormone releasing properties, pharmaceutical compositions comprising thereof and their use
JP2001523232A (en) GnRH antagonist
US5106834A (en) Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
JPH0219397A (en) Novel linear derivatives of alginin vasopressin antagonist
JPS63154699A (en) Vasopressin antagonism
WO2018128828A1 (en) Novel hepcidin mimetics and uses thereof
JPS61191698A (en) Novel cyclic hexapeptide lhrh antagonistic
SE501677C2 (en) Biologically active vasopressin analogs, pharmaceutical preparations containing them and their use in the manufacture of drugs
CA2405704C (en) Bombesin analogs for treatment of cancer
AU676071B2 (en) Peptides exhibiting oxytocin antagonistic activity
KR0171614B1 (en) Vasoactive vasotocin derivatives
EP1198478B1 (en) Somatostatin analogs and their use for the treatment of cancer
IE912378A1 (en) Derivatives of pituitary posterior lobe hormones
US6989371B1 (en) Bombesin analogs for treatment of cancer
JPS63303999A (en) Vasopressin antagonist
WO2002000688A1 (en) Peptide compound and pharmaceutical compositions and medicines containing the same as the active ingredient

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980201